Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251840 | 0.77 | HSD11B1 (0.50) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL12714 | 0.74 | HSD11B1 (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL19557166 | 0.74 | HSD11B1 (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| Ammonia Solution, Strong SCHEMBL11787415 | 0.74 | HSD11B1 (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL19557168 | 0.74 | HSD11B1 (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL546352 | 0.74 | HTT (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL133056 | 0.74 | HSD11B1 (0.48) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL10849186 | 0.74 | ALDH1A1 (0.39) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| SCHEMBL5489940 | 0.72 | HSD11B1 (0.46) | EPHX1EPHX2HSD11B1L3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL1061147 | 0.72 | L3MBTL1 (0.50) | EPHX1EPHX2HSD11B1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452521-A1 | TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192226-A1 | TETRAHYDROINDACENYL CATALYST COMPOSITION, CATALYST SYSTEM, AND PROCESSES FOR USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-11-09 | — | — | WO | claimed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| JP-4242067-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| EP-1022272-B1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | SANKYO CO (JP) | 2004-05-26 | — | — | EP | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-0837887-B1 | POLYMERIZATION OF CRYSTALLINE COPOLYMERS OF OLEFINS AND CYCLIC OLEFINS | EXXONMOBIL CHEM PATENTS INC (US) | 2001-11-28 | — | — | EP | claimed |
| US-6319998-B1 | MAKING BLENDS OF ETHYLENE-PROPYLENE-OPTIONAL DIENE COPOLYMERS IN WHICH THE BLEND COMPONENTS DIFFER IN COMPOSITION, MOLECULAR WEIGHT, OR CRYSTALLINITY USING A METALLOCENE CATALYST. | EXXON MOBIL CHEMICAL PATENTS INC. | 2001-11-20 | — | — | US | claimed |
| EP-1060202-A1 | METHOD FOR MAKING POLYMER BLENDS BY USING SERIES REACTORS | EXXON CHEMICAL PATENTS INC. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-1060199-A1 | METHOD FOR INCREASING DIENE CONVERSION IN EPDM TYPE POLYMERIZATIONS | Exxon Chemical Patents, Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | claimed |
| WO-1999045047-A1 | METHOD FOR INCREASING DIENE CONVERSION IN EPDM TYPE POLYMERIZATIONS | EXXON CHEMICAL PATENTS INC. (US) | 1999-09-10 | — | — | WO | claimed |
| WO-1999045049-A1 | METHOD FOR MAKING POLYMER BLENDS BY USING SERIES REACTORS | EXXON CHEMICAL PATENTS INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-5208228-A | Skin disorders | MERCK & CO., INC. (US) | 1993-05-04 | — | — | US | claimed |
| EP-0428365-A1 | Aminomacrolides and derivatives having immunosuppressive activity | MERCK & CO. INC. (US) | 1991-05-22 | — | — | EP | claimed |
| US-4014892-A | ANTHELMINTICS | AMERICAN CYANAMID COMPANY (US) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | EPHX1 1869/4885EPHX2 2941/4885HSD11B1 3068/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | EPHX1 1803/4885EPHX2 2978/4885HSD11B1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.